Articles tagged with Toll Like Receptors
Researchers from the University of Bonn have developed a new method to study immune receptors using a label-free biosensor assay. This approach allows for the detection of specific chemical signals that activate Toll-like receptors (TLRs), which are found on the surface of immune cells and play a crucial role in detecting infections. T...
A meta-analysis found that individuals carrying the AA genotype at TLR10 rs10004195 locus have a significantly elevated risk of H. pylori infection. This association may be used to assess future risk and provide personalized health guidance.
Researchers describe redundant innate immune pathways triggered by AAV vectors, including sensing of viral genome and cytoplasmic DNA sensors. The study highlights the need to understand complex biologic mechanisms underlying adverse reactions to AAV vectors in human gene therapy trials.
LMU researchers identified key enzymes involved in recognizing foreign RNA for TLR7 activation, including RNase T2 and PLD exonucleases. These findings provide important insights into the complex activation mechanism of TLR7, which plays a crucial role in defending against viruses.
Researchers found that bisphenol A (BPA) inactivates microbial lipopolysaccharides (LPS), a key trigger for allergic asthma. This disruption increases susceptibility to asthma in mice, highlighting a potential link between BPA exposure and immune disorders.
The study found that black soldier fly larvae oil exhibits anti-inflammatory properties, suppressing proinflammatory cytokines and improving colon health. BSFL oil's unique compound profile may offer a new approach to managing inflammatory diseases.
Researchers found that morphine interacts with toll-like receptor 4 to contribute to increased bone loss and pain. Blocking TLR4 prevents these effects, suggesting a new target for reducing opioid side effects.
Researchers identified genetic variants associated with susceptibility to Epizootic Hemorrhagic Disease (EHD) in white-tailed deer. The study found that deer with specific mutations are less susceptible to the disease, which has been on the rise in northern Illinois and neighboring states.
Researchers have found that brexanolone works by inhibiting systemic inflammatory pathways associated with depression. The study suggests that inflammation may contribute to the development of post-partum depression.
A new neuroprotectant medication called ApTOLL has been shown to improve survival and reduce long-term disability among patients with stroke. The study found that ApTOLL, when used in conjunction with standard treatments, reduced death and brain damage, suggesting a promising new approach to treating stroke.
Research shows COVID-19 can cause long-term changes to brain function through inflammation, affecting mood, concentration, and cognitive abilities in both young and old patients. Millions are potentially affected by this condition, also known as Long COVID.
Researchers identified toll-like receptor (TLR) signaling as a novel pathway regulating GLI3 expression, which plays a role in inflammatory cytokine production and cancer. They found that IRF3 directly binds to the GLI3 promoter region, increasing its expression upon TLR4 stimulation.
Macrophages change their metabolism drastically after coming into contact with bacteria, triggering an inflammatory response. This process involves the activation of Toll-like receptors, which leads to histone acetylation and changes in gene expression.
Researchers have discovered a lipid called phosphatidylglycerol (PG) that may help restore healthy skin turnover in people with psoriasis. PG reduced inflammation and raised skin lesions when applied topically to a mouse model of psoriasis, suggesting it could be a new treatment option.
Researchers have found evidence that dissolving NETs can reduce swelling and improve blood flow after traumatic brain injuries. A drug called DNase, which is currently used to thin out lung mucus in cystic fibrosis, appears to dissolve NETs and has shown promise in reducing swelling and improving recovery.
Researchers have discovered a potent drug-like compound that inhibits Toll-like receptor 8, a key player in autoimmune diseases. The compound, CU-CPT8m, exerts potent anti-inflammatory effects on tissue, offering a potential breakthrough for treating rheumatoid arthritis and other autoimmune conditions.
Researchers developed nanofiber sutures loaded with 25-hydroxyvitamin D3 and pam3CSK4 peptide, releasing the former on a sustained basis over four weeks. The sutures activated immune responses, producing the LL-37 peptide that kills microbes by disrupting their membranes.
Scientists at HZI have shown that herpesviruses like KSHV and MHV68 modulate the TLR-induced proinflammatory cytokine response, allowing them to remain within the body for a long time. The researchers discovered that the virus actively prevents activation of the innate immune system through Toll-like receptors.
Researchers found that toll-like receptor 4 is activated by fibrinogen cleavage products, which are generated by proteinase enzymes. This activation leads to the production of pro-inflammatory cytokines and the recruitment of immune cells to the airways, resulting in asthma-like symptoms.
Recent research reveals that Toll-like receptor 4 expressed in cerebral cortical neurons stimulates inflammatory pathways, suggesting that neurons may be both passive victims and activators of neuroinflammation. Lipopolysaccharide triggers the Toll-like receptor 4/nuclear factor-κB pathway, leading to neuroinflammatory responses.
The Lupus Research Institute has awarded $1 million to University of Massachusetts Medical School faculty for research on toll-like receptors in lupus. The award will explore the role of TLR proteins in the disease and identify new targets for therapies.
New research reveals that Toll-like receptors play a major role in brain damage risk for newborns, contributing to conditions like cerebral palsy and epilepsy. The discovery could lead to more effective treatment strategies, such as blocking special TLRs to reduce brain damage following hypoxia.
A researcher at Michigan State University is studying the role of the innate immune system in protecting against lung cancer. Alison Bauer's work may lead to new approaches to prevent, identify and treat lung cancer.
Researchers discovered that a 1966 RSV vaccine's defective antibodies failed to bind to the real virus, leading to severe disease. New findings could lead to the development of safer and more effective vaccines for RSV and other respiratory viruses.
Research shows Lactobacillus bulgaricus can prevent H. pylori lipopolysaccharide-activated TLR4 pathway, reducing IL-8 production and promoting gastric epithelial cell survival. The study suggests a novel relationship between probiotics and pathogenic bacteria in regulating inflammatory responses.
Researchers at Emory University School of Medicine discovered that human arteries play distinct roles in the immune system depending on their anatomical location. Different types of arterial samples had varying Toll-like receptor gene expressions, which may explain why certain vascular diseases affect specific parts of the body.
New research led by Brown University immunologist Wen-Ming Chu has uncovered a direct interaction between high-mobility group box 1 protein and toll-like receptor 9, triggering the immune response. The discovery could lead to the development of new vaccines and treatments for diseases such as cancer, asthma, and allergies.
The structure reveals new details about TLR3's binding site for double-stranded RNA and its potential role in detecting viral invaders. This breakthrough may help scientists understand the function of TLR proteins and identify potential therapeutic targets for diseases.
A new study published in the Journal of Clinical Investigation has identified an antagonistic antibody that can prevent sepsis by blocking toll-like receptor 2-driven shock-like syndromes. The discovery offers new hope for combating this deadly condition.